EU/3/19/2186
Table of contents
About
On 25 July 2019, orphan designation EU/3/19/2186 was granted by the European Commission to Takeda Pharma A/S, Denmark, for pevonedistat for the treatment of acute myeloid leukaemia.
The sponsor’s address was updated in August 2020.
Key facts
Active substance |
Pevonedistat
|
Disease / condition |
Treatment of acute myeloid leukaemia
|
Date of first decision |
25/07/2019
|
Outcome |
Positive
|
EU designation number |
EU/3/19/2186
|
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor's contact details
Takeda Pharma A/S
Delta Park 45
2665 Vallensbaek Strand
Hovedstaden
Danmark
Tel: +45 4677 1111
E-mail: kristina.stovring@takeda.com
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.